Chimeric Antigen Receptor Assembly via Modular Library Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for adoptive T cell transfer in cancer treatment face challenges in predicting which Chimeric Antigen Receptors (CARs) will effectively target specific cancers, due to significant variability in therapeutic potential across patient populations, making it difficult to anticipate which CARs will display therapeutic activity against a given cancer or its subtype.
Innovation Solution
The development of methods for generating and screening a large number of CARs using the EZ-CAR Platform, which allows for high-throughput assembly of CAR molecules by combining antigen binding domains, hinge regions, and intracellular signaling domains, enabling personalized therapy by identifying CARs with improved therapeutic potential for specific cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional methods for generating CARs are used, then the process is simple, but the ability to identify effective CARs for specific cancers is limited due to significant variability in therapeutic potential across patient populations
Solution Approach 1:
The patent segments the CAR generation process into distinct modules: library construction with diverse CAR variants, high-throughput screening systems, and computational prediction algorithms. This segmentation allows each component to be optimized independently, improving the ability to identify effective CARs while managing overall system complexity through modular architecture.
Solution Approach 2:
The patent employs parameter changes by systematically varying multiple CAR design parameters (antigen binding domains, hinge regions, transmembrane domains, intracellular signaling domains) to generate diverse CAR libraries. This approach enables the identification of optimal parameter combinations for specific cancer types and patient populations, directly addressing the variability in therapeutic potential.
2Reliability
If a large number of CARs are generated and screened, then the likelihood of identifying effective CARs increases, but the time and resources required for the process increase significantly
Solution Approach 1:
The patent applies preliminary action through computational prediction algorithms that assess CAR potential before experimental testing. This pre-screening step filters out unlikely candidates, allowing the high-throughput screening process to focus on a reduced set of promising CAR variants, thereby maintaining high identification reliability while reducing overall processing time.
Solution Approach 2:
The patent substitutes mechanical/experimental testing with computational prediction methods for the initial assessment phase. By using in silico modeling and bioinformatics approaches to evaluate CAR candidates before wet-lab experiments, the system maintains high reliability in identifying effective CARs while dramatically reducing the time and resource investment required.
3Manufacturing precision
If personalized CAR therapy is implemented for individual patients, then treatment efficacy is improved, but the manufacturing complexity and cost increase
Solution Approach 1:
The patent implements universality through standardized modular CAR components that can be recombined to create patient-specific CAR designs. The universal platform includes standardized hinge regions, transmembrane domains, and signaling domains that work across different antigen targets and patient populations, reducing manufacturing complexity while maintaining personalization capability.
Solution Approach 2:
The patent applies local quality by customizing only the antigen-binding domain (scFv) portion of the CAR based on patient-specific tumor antigens, while keeping the remaining CAR structure standardized. This approach enables personalized therapy for individual patients with specific cancer types while minimizing the increase in manufacturing complexity by limiting customization to a single functional region.
Data Source
AI summary
Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.